|
G蛋白偶联受体
G蛋白偶联受体（GPCRs）是一类与G蛋白偶联的细胞表面受体，具有7个跨膜α螺旋结构。G蛋白偶联受体(GPCRs)能接受许多细胞外信号并传递给G蛋白，进而启动细胞内不同的信号转导通路。GPCRs介导对环境刺激物、神经递质、激素、细胞因子和脂质信号分子的多种生理反应，从而在视觉、嗅觉、自主神经系统和行为等生物过程中发挥着重要作用。GPCRs还与众多疾病相关，是治疗许多疾病的重要靶点之一。异常的GPCR功能与病理状态有关，如神经、免疫和激素紊乱等。
G蛋白偶联受体信号通路转导过程
G 蛋白偶联受体可被多种不同的外界刺激激活。当配体与GPCRs结合时，激活附着在细胞内侧端的G蛋白（由α、β、γ三个亚基组成的异源三聚体）。G蛋白上原本结合的GDP被GTP取代，导致α亚基与β-γ亚基复合物解离，并触发各种不同的信号级联放大，激活下游信号通路。这些细胞内信号通路包括cAMP/PKA、钙/NFAT、磷脂酶C（PLC)、蛋白酪氨酸激酶、MAP激酶、PI3K、NO/cGMP、Rho和JAK/STAT等，从而作用于相应的靶分子，进而调控代谢过程及基因表达功能。
G蛋白偶联受体信号通路图
产品列表
按靶点分类：
*5-HT受体
| 项目号 |
产品名称 |
规格 |
CAS |
包装 |
细胞 |
靶点 |
IC50 |
Ki |
pKi |
| F131623 |
Fluoxetine HCl |
≥98%(HPLC) |
56296-78-7 |
1g,5g,25g |
|
5-HT |
0.1 pM |
|
|
| V129637 |
Venlafaxine hydrochloride |
≥98%(HPLC) |
99300-78-4 |
1g,5g,25g,100g |
|
5-HT |
|
|
|
| D129639 |
Dapoxetine hydrochloride |
≥98%(HPLC) |
129938-20-1 |
250mg,1g,5g |
|
5-HT |
|
|
|
| I125279 |
Iloperidone |
≥98% |
133454-47-4 |
50mg,250mg,1g,5g |
|
5-HT |
|
|
|
| V129787 |
Vortioxetine (Lu AA21004) HBr |
≥98% |
960203-27-4 |
5mg,25mg,100mg |
|
5-HT1A |
15 nM |
|
|
| 5-HT1B |
33 nM |
|
|
| 5-HT3A |
3.7 nM |
|
|
| 5-HT7受体 |
19 nM |
|
|
| SERT |
1.6 nM |
|
|
| F129671 |
Fluvoxamine maleate |
≥98% |
61718-82-9 |
250mg,1g,5g,25g,100g |
|
5-HT |
|
|
|
| S129789 |
Sertraline HCl |
≥98% (HPLC) |
79559-97-0 |
1g,5g |
|
5-HT |
|
|
|
| L129555 |
Lamotrigine |
≥98% |
84057-84-1 |
1g,5g |
人类血小板 |
5-HT |
240 μM |
|
|
| 大鼠脑突触体 |
5-HT |
474 μM |
|
|
| C129687 |
Clomipramine HCl |
≥99% |
17321-77-6 |
1g,5g,25g |
|
5-HT |
|
|
|
| E122736 |
草酸右旋西酞普兰 |
98% |
219861-08-2 |
50mg,250mg,1g,5g |
|
5-HT |
|
0.89 nM |
|
| D123291 |
盐酸度洛西汀 |
≥98.0%(HPLC) |
136434-34-9 |
1g,5g,25g |
|
5-HT |
|
|
|
| M129386 |
Milnacipran hydrochloride |
≥99% |
101152-94-7 |
10mg,50mg,250mg,500mg,1g,5g,25g |
|
NET |
77 nM |
|
|
| SERT |
420 nM |
|
|
| A129730 |
盐酸阿米替林 |
≥98% |
549-18-8 |
1g,5g,25g,100g |
|
5-羟色胺受体 |
3.45 nM |
|
|
| 去甲肾上腺素受体 |
13.3 nM |
|
|
| 5-HT4 |
7.31 nM |
|
|
| 5-HT2 |
235 nM |
|
|
| sigma 1受体 |
287 nM |
|
|
| L174987 |
Levomilnacipran hydrochloride |
97% |
175131-60-9 |
100mg,250mg,1g |
|
|
|
|
|
| C122737 |
氢溴酸西酞 |
98% |
59729-32-7 |
1g,5g |
|
serotonin reuptake |
1.8 nM |
|
|
| V129637 |
Venlafaxine hydrochloride |
≥98% (HPLC) |
93413-69-5 |
1g,5g,25g,100g |
|
SNRI |
|
|
|
| D136408 |
盐酸去甲咪嗪 |
≥98% |
58-28-6 |
1g,5g,25g |
|
|
|
|
|
| T129695 |
曲唑酮 盐酸盐 |
98% |
25332-39-2 |
1g |
|
5-HT |
|
|
|
| P137447 |
Protriptyline Hydrochloride |
≥98% |
1225-55-4 |
25mg,100mg |
|
|
|
|
|
| A129721 |
Atomoxetine HCl |
≥98% |
82248-59-7 |
50mg,250mg,1g |
|
Norepinephrine (NE) transporter |
|
5 nM |
|
| 5-HT |
|
77 nM |
|
| DA transporter |
|
1451 nM |
|
| C126883 |
氯氮平 |
≥98%(GC) |
5786-21-0 |
100mg,1g,5g,25g,100g |
|
5-HT |
110 nM |
|
|
| O126519 |
Olanzapine |
≥99% |
132539-06-1 |
1g,5g |
|
5-HT2 |
|
|
|
| D2 receptor |
|
|
|
| K129651 |
Ketanserin |
≥97% |
74050-98-9 |
50mg,250mg,1g |
|
5-HT2A |
|
2.5 nM |
|
| 大鼠 |
5-HT2C |
|
50 nM |
|
| 人 |
5-HT2C |
|
100 nM |
|
| L129669 |
Latrepirdine |
≥96% |
97657-92-6 |
5mg,10mg,50mg |
|
|
|
|
|
| A129730 |
盐酸阿米替林 |
≥98% |
50-48-6 |
1g,5g,25g,100g |
|
|
|
|
|
| A124691 |
阿戈美拉汀 |
≥98%(HPLC) |
138112-76-2 |
5mg,25mg,50mg,250mg,1g,5g,25g |
|
5-HT2C |
|
|
|
| A124739 |
Asenapine maleate |
≥98% (HPLC) |
85650-56-2 |
10mg,50mg,250mg,1g |
|
|
|
|
|
| R127644 |
Risperidone |
≥98% |
106266-06-2 |
500mg,5g,25g,100g |
|
5-HT2A |
|
0.17 nM |
|
| α2c-adrenergic receptor |
|
1.3 nM |
|
| D2 receptor |
|
3.57 nM |
|
| D3 receptor |
|
3.6 nM |
|
| D2L Receptor |
|
4.16 nM |
|
| E129717 |
Ziprasidone HCl |
≥98% |
122883-93-6 |
250mg,1g |
|
5-HT receptor |
|
|
|
| Dopamine receptor |
|
|
|
| W129689 |
WAY-100635 Maleate |
≥99% |
1092679-51-0 |
5mg,25mg,100mg |
|
5-HT |
0.95 nM |
|
|
| B129706 |
Blonanserin |
≥98% (HPLC) |
132810-10-7 |
25mg,100mg |
|
dopamine D2 receptor |
|
14.8 nM |
|
| 5-HT2 |
|
3.98 nM |
|
| S129658 |
SB269970 HCl |
≥99% |
261901-57-9 |
10mg,50mg |
|
5-HT7 |
|
|
8.3 |
| S125056 |
SB269970 HCl |
- |
261901-57-9 |
10mg |
|
5-HT7 |
|
|
8.3 |
| G120176 |
盐酸格拉司琼 |
98% |
107007-99-8 |
10mg,50mg,1g,5g |
|
5-HT3 |
|
|
|
| M129297 |
Mirtazapine |
≥98% |
85650-52-8 |
100mg,1g |
|
5-HT |
|
|
|
| SB742457 |
SB742457 |
≥97% |
607742-69-8 |
5mg,25mg |
|
5-HT6 |
|
|
9.63 |
| B129690 |
BRL-15572 |
≥99% |
193611-72-2 |
5mg,10mg,50mg |
|
5-HT1D |
|
|
7.9 |
| P129785 |
PRX-08066 Maleic acid |
≥99% |
866206-55-5 |
5mg,10mg,50mg |
|
5-HT2B |
3.4 nM |
|
|
| T124762 |
盐酸托烷司琼 |
≥98.0% |
105826-92-4 |
250mg,1g,5g |
|
5-HT3 |
70.1±0.9 nM |
|
|
| P129438 |
Pizotifen Malate |
≥99% |
5189-11-7 |
100mg,500mg |
|
|
|
|
|
| A129701 |
Azasetron HCl |
≥99% |
123040-16-4 |
25mg,100mg |
|
5-HT3 |
0.33 nM |
|
|
| F129636 |
夫洛丙酮 |
≥99% |
2295-58-1 |
50mg |
|
5-HT1A |
|
|
|
| O129694 |
Ondansetron |
≥99% |
99614-02-5 |
10mg,50mg,250mg |
|
5-HT3 |
|
|
|
| P129744 |
Palonosetron HCl |
≥99% |
135729-62-3 |
100mg,500mg |
|
5-HT3 |
|
|
|
| V129763 |
VUF 10166 |
≥99% |
155584-74-0 |
10mg,50mg,250mg |
|
5-HT3A |
|
0.04 nM |
|
| 5-HT3AB |
|
22 nM |
|
| N159830 |
奈法唑酮盐酸盐 |
98.00% |
82752-99-6 |
200mg,1g |
|
|
|
|
|
| C101491 |
盐酸赛庚啶 |
98% |
41354-29-4 |
1g,5g,25g |
|
5-HT2 |
|
0.6 nM |
|
| O129679 |
Ondansetron Hydrochloride Dihydrate |
≥98% (HPLC) |
103639-04-9 |
1g,5g |
|
5-HT3 receptor |
|
6.16 nM |
|
| A135530 |
Alosetron Hydrochloride |
≥98% (HPLC) |
122852-69-1 |
1g,5g |
|
5-HT3 receptor |
|
|
|
| S132232 |
Sarpogrelate Hydrochloride |
≥98% |
135159-51-2 |
5mg,25mg,100mg |
|
5-HT2A |
|
|
8.52 |
| 5-HT2C |
|
|
7.43 |
| 5-HT2B |
|
|
6.57 |
| R166990 |
Ramosetron hydrochloride |
98% (HPLC) |
132907-72-3 |
10mg,50mg,100mg,250mg |
|
5-HT3 receptor |
|
0.091 nM |
|
| P111270 |
葛根素 |
98% |
3681-99-0 |
1g,5g,25g,100g |
|
5-HT2C |
|
|
|
| P111269 |
葛根素 |
分析标准品,≥98% |
3681-99-0 |
20mg |
|
5-HT2C |
|
|
|
| C134704 |
Cyclobenzaprine hydrochloride |
98% |
6202-23-9 |
1g,5g,25g |
|
5-HT2 receptor |
|
|
|
| G127257 |
Granisetron |
- |
109889-09-0 |
25mg,50mg,100mg,250mg |
|
5HT-3 |
|
|
|
| L129692 |
LY310762 |
≥95% |
192927-92-7 |
10mg,50mg |
|
5-HT1D |
249 nM |
|
|
| P125293 |
Palonosetron |
- |
135729-61-2 |
10mg,100mg |
|
5-HT3 receptor |
|
0.17 nM |
|
| M124574 |
5-甲氧基色胺 |
97% |
608-07-1 |
250mg,1g,5g,25g |
|
5-HT1 |
|
|
|
| 5-HT2 |
|
|
|
| 5-HT4 |
|
|
|
| 5-HT6 |
|
|
|
| S129681 |
Sumatriptan Succinate |
≥98% (HPLC) |
103628-48-4 |
50mg,100mg,250mg,1g |
|
|
|
|
|
| P129662 |
Prucalopride |
≥99% |
179474-81-8 |
10mg,50mg |
|
5-HT4A |
|
2.5 nM |
|
| 5-HT4B |
|
8 nM |
|
| A124880 |
Aripiprazole |
≥99% |
129722-12-9 |
1g,5g |
|
5-HT1A |
|
4.2 nM |
|
| N129630 |
Naratriptan hydrochloride |
≥98% |
143388-64-1 |
10mg,25mg,50mg,100mg |
|
5-HT |
|
|
|
| R129638 |
Rizatriptan Benzoate |
≥98%(HPLC) |
145202-66-0 |
10mg,50mg,250mg,1g,5g |
|
5-HT1 |
|
|
|
| Z129649 |
Zolmitriptan |
≥98%(HPLC) |
139264-17-8 |
200mg,250mg,1g,5g,25g |
|
5-HT |
|
|
|
| M129673 |
Mosapride Citrate |
≥98% |
112885-42-4 |
10mg,50mg,250mg,1g,5g,25g |
|
5-HT4 |
|
|
|
| E129729 |
Eletriptan HBr |
≥98% |
177834-92-3 |
10mg,50mg,250mg,1g,5g |
|
5-HT1B |
|
0.92 nM |
|
| 5-HT1D |
|
3.14 nM |
|
| A129703 |
Almotriptan Malate |
≥99% |
181183-52-8 |
1g |
|
5-HT1B |
|
|
|
| 5-HT1D |
|
|
|
| T168187 |
Tegaserod maleate |
98% (HPLC) |
189188-57-6 |
10mg,50mg |
|
5-HT4 receptor |
|
|
|
| B129734 |
BRL-54443 |
≥98% |
57477-39-1 |
10mg,50mg,100mg |
|
5-HT1E |
|
|
8.7 |
| 5-HT1F |
|
|
9.25 |
| B178171 |
brexpiprazole |
97% |
913611-97-9 |
1g |
|
D2L |
|
0.3 nM |
|
| 5-HT1A |
|
0.12 nM |
|
| 5-HT2A |
|
0.47 nM |
|
| α1B受体 |
|
0.17 nM |
|
| α2C受体 |
|
0.59 nM |
|
| M179481 |
Mosapride |
95% |
112885-41-3 |
1g,5g |
|
5HT4 |
|
|
|
| S111161 |
血清胺盐酸盐 |
AR |
153-98-0 |
1g,5g,25g |
|
5-HT |
|
|
|
| V124992 |
Vilazodone |
≥98% |
163521-12-8 |
10mg,50mg |
|
|
|
|
|
| F167802 |
Flibanserin |
98% (HPLC) |
167933-07-5 |
5mg,25mg |
|
5-HT1A |
|
1 nM |
|
| 5-HT2A |
|
49 nM |
|
| F167802 |
Vortioxetine |
≥98% |
508233-74-7 |
10mg,50mg,250mg,1g |
|
|
|
|
|
| P129402 |
Azacyclonol |
≥99% |
115-46-8 |
50mg |
|
|
|
|
|
*肾上腺素受体
| 项目号 |
产品名称 |
规格 |
CAS |
包装 |
靶点 |
IC50 |
Ki |
pKi |
Kd |
EC50 |
ED50 |
pEC50 |
| D129796 |
甲磺酸多沙唑嗪 |
≥99% |
77883-43-3 |
50mg,100mg,250mg,1g,5g,25g,100g |
α-1肾上腺素能受体 |
|
|
|
|
|
|
|
| I129899 |
Ivabradine HCl |
≥98% |
148849-67-6 |
250mg,1g,5g |
肾上腺素受体 |
2.9 μM |
|
|
|
|
|
|
| C129903 |
Cisatracurium Besylate |
≥98% |
96946-42-8 |
1g |
肾上腺素受体 |
|
|
|
|
|
|
|
| A124739 |
Asenapine maleate |
≥98% (HPLC) |
85650-56-2 |
10mg,50mg,250mg,1g |
5-HT2C |
|
|
10.46 |
|
|
|
|
| 5-HT2A |
|
|
10.15 |
|
|
|
|
| 5-HT7 |
|
|
9.94 |
|
|
|
|
| 5-HT2B |
|
|
9.75 |
|
|
|
|
| 5-HT6 |
|
|
9.6 |
|
|
|
|
| C141489 |
卡拉洛尔 |
98% |
57775-29-8 |
250mg,1g |
|
|
|
|
|
|
|
|
| C120231 |
卡拉洛尔 |
分析标准品 |
57775-29-8 |
10mg |
|
|
|
|
|
|
|
|
| A129804 |
Alfuzosin hydrochloride |
≥98% |
81403-68-1 |
50mg,100mg,250mg,1g |
α1受体 |
|
|
|
|
|
|
|
| S126595 |
Silodosin |
≥99% |
160970-54-7 |
5mg,25mg,100mg,250mg,1g |
|
|
|
|
|
|
|
|
| N129836 |
Nebivolol hydrochloride |
≥97% |
152520-56-4 |
10mg,20mg,100mg,1g,5g |
β1-肾上腺素受体 |
0.8 nM |
|
|
|
|
|
|
| B129688 |
BMY 7378 dihydrochloride |
≥98% |
21102-95-4 |
10mg,50mg,100mg |
α2C肾上腺素受体 |
|
|
6.54 |
|
|
|
|
| α1D肾上腺素受体 |
|
|
8.2 |
|
|
|
|
| 5-HT1A受体 |
|
|
8.3 |
|
|
|
|
| P160142 |
Prazosin Hydrochloride |
≥98.0% |
19237-84-4 |
50mg,250mg,1g |
α肾上腺素受体 |
|
|
|
|
|
|
|
| P123277 |
甲磺酸酚妥拉明 |
≥98.0%(TLC) |
65-28-1 |
100mg,500mg,5g |
α-肾上腺素受体 |
0.1 μM |
|
|
|
|
|
|
| M111945 |
酒石酸美托洛尔 |
98% |
56392-17-7 |
5g |
β-肾上腺素能受体 |
42 ng/mL |
|
|
|
|
|
|
| M111944 |
酒石酸美托洛尔 |
分析标准品 |
56392-17-7 |
1g |
β-肾上腺素能受体 |
42 ng/mL |
|
|
|
|
|
|
| T129895 |
Terazosin hydrochloride Dihydrate |
≥98% |
70024-40-7 |
100mg,5g,25g |
α-肾上腺素能受体 |
|
|
|
|
|
|
|
| M129850 |
Maprotiline HCl |
≥99%(HPLC) |
10347-81-6 |
1g,5g,25g |
肾上腺素受体 |
|
|
|
|
|
|
|
| C123267 |
Carvedilol |
≥98%(HPLC) |
72956-09-3 |
1g,5g,25g |
α1肾上腺素受体 |
|
|
|
|
|
|
|
| β1肾上腺素受体 |
|
|
|
|
|
|
|
| N129805 |
Naftopidil |
≥98.0% |
57149-07-2 |
5g,25g,500g |
α1-肾上腺素能受体 |
|
58.3 nM |
|
|
|
|
|
| P129843 |
Phenoxybenzamine HCl |
≥98% |
63-92-3 |
1g,5g,25g |
α受体拮抗剂 |
550 nM |
|
|
|
|
|
|
| A129820 |
Acebutolol HCl |
≥99% |
34381-68-5 |
250mg |
β-肾上腺素能受体 |
|
|
|
|
|
|
|
| B129336 |
Buflomedil HCl |
≥98% |
35543-24-9 |
1g,5g,25g,100g,500g |
α-肾上腺素受体 |
|
|
|
|
|
|
|
| C134671 |
cis-(Z)-Flupentixol Dihydrochloride |
≥98% (HPLC) |
51529-01-2 |
250mg |
α肾上腺素能受体 |
|
|
|
|
|
|
|
| A132124 |
阿普洛尔 盐酸盐 |
≥99% |
13707-88-5 |
50mg,250mg |
β-肾上腺素能受体 |
|
|
|
|
|
|
|
| M171294 |
Moxisylyte hydrochloride |
>99% (TLC) |
964-52-3 |
25g |
α-肾上腺素受体 |
|
|
|
|
|
|
|
| A151072 |
Atipamezole Hydrochloride |
98% |
104075-48-1 |
25mg,100mg,250mg,1g |
α2肾上腺素能受体 |
|
|
|
|
|
|
|
| A132977 |
Atipamezole |
≥98% (HPLC) |
104054-27-5 |
5mg,25mg,100mg,1g |
α2肾上腺素能受体 |
|
|
|
|
|
|
|
| P160771 |
吡贝地尔 |
>98.0%(GC)(T) |
3605-01-4 |
200mg,1g |
α2C肾上腺素受体 |
|
|
7.2 |
|
|
|
|
| α2A肾上腺素受体 |
|
|
7.1 |
|
|
|
|
| D2肾上腺素受体 |
|
|
6.9 |
|
|
|
|
| T102080 |
盐酸坦索罗辛 |
98% |
106463-17-6 |
100mg,500mg,1g |
α1A肾上腺素受体 |
|
|
|
|
|
|
|
| T136685 |
Terazosin Hydrochloride |
>98.0%(HPLC) |
63074-08-8 |
50mg,250mg,1g |
α-AR |
|
|
|
|
|
|
|
| D193380 |
盐酸贝凡洛尔 |
98% |
42864-78-8 |
250mg,1g,5g |
β肾上腺素受体 |
|
|
|
|
|
|
|
| B129900 |
Betaxolol |
≥98% |
63659-18-7 |
10mg,50mg,250mg |
β1肾上腺素能受体 |
|
|
|
|
|
|
|
| A124776 |
阿替洛尔 |
≥98%,powder |
29122-68-7 |
1g,5g,25g,100g |
β1肾上腺素受体 |
|
|
|
0.25 μM |
|
|
|
| β2肾上腺素受体 |
|
|
|
1 μM |
|
|
|
| Y111137 |
盐酸育亨宾 |
99% |
65-19-0 |
1g,5g,25g |
α2肾上腺素受体 |
|
|
|
|
|
|
|
| Y111138 |
盐酸育亨宾 |
分析标准品,≥99% |
65-19-0 |
20mg |
α2肾上腺素受体 |
|
|
|
|
|
|
|
| Y140628 |
盐酸育亨宾 |
97% |
65-19-0 |
1g,5g,25g |
α2肾上腺素受体 |
|
|
|
|
|
|
|
| L133648 |
Labetalol HCl |
98% |
32780-64-6 |
50mg,250mg,1g |
α1肾上腺素受体 |
|
|
|
|
|
|
|
| β肾上腺素受体 |
|
|
|
|
|
|
|
| M126688 |
Mirabegron |
≥99% |
223673-61-8 |
5mg,10mg,50mg,250mg,1g |
β3肾上腺素受体 |
|
|
|
|
22.4 nM |
|
|
| X113957 |
盐酸甲苯噻嗪 |
分析标准品 |
23076-35-9 |
100mg |
α2肾上腺素能受体 |
|
|
|
|
|
|
|
| X113956 |
盐酸甲苯噻嗪 |
98% |
23076-35-9 |
1g,5g,25g,100g |
α2肾上腺素能受体 |
|
|
|
|
|
|
|
| D194797 |
盐酸阿可乐定(曾用名:盐酸安普乐定) |
97% |
73218-79-8 |
25mg,100mg,250mg,1g,5g |
α2-肾上腺素能受体 |
|
|
|
|
|
|
|
| I157518 |
茚达特罗马来酸盐 |
>98.0%(HPLC) |
753498-25-8 |
20mg,25mg,50mg,100mg,1g |
β1肾上腺素受体 |
|
|
7.36 |
|
|
|
|
| β2肾上腺素受体 |
|
|
5.48 |
|
|
|
|
| I129810 |
盐酸异丙肾上腺素 |
≥99% |
51-30-9 |
5g,25g,100g |
β肾上腺素受体 |
|
|
|
|
|
|
|
| F129812 |
Formoterol Hemifumarate |
≥99% |
43229-80-7 |
10mg,50mg |
β2肾上腺素受体 |
|
|
|
|
|
|
|
| E129809 |
酒石酸肾上腺素 |
≥98% |
51-42-3 |
1g,5g,25g |
α肾上腺素能受体 |
|
|
|
|
|
|
|
| β肾上腺素受体 |
|
|
|
|
|
|
|
| C102161 |
盐酸可乐定 |
98% |
4205-91-8 |
250mg,1g,5g,100g |
α2肾上腺素能受体 |
|
|
|
|
|
0.02±0.01 mg/kg |
| D129407 |
Droxidopa |
≥98% |
23651-95-8 |
50mg,250mg |
|
|
|
|
|
|
|
|
| D129818 |
Dexmedetomidine |
≥98% |
113775-47-6 |
50mg,250mg |
α2肾上腺素能受体 |
|
|
|
|
|
|
|
| P106007 |
盐酸去氧肾上腺素 |
99% |
61-76-7 |
5g,10g,25g,50g,100g |
α1肾上腺素能受体 |
|
|
|
|
|
|
|
| G156852 |
氯苄氨胍醋酸盐 |
>98.0%(HPLC) |
23256-50-0 |
200mg,1g,5g |
α2a-肾上腺素能受体 |
|
|
|
|
|
|
8.25 |
| α2b-肾上腺素能受体 |
|
|
|
|
|
|
7.01 |
| α2c-肾上腺素能受体 |
|
|
|
|
|
|
<5 |
| N113459 |
Naphazoline hydrochloride |
99% |
550-99-2 |
5g,25g,100g,500g |
|
|
|
|
|
|
|
|
| R124692 |
利托君盐酸盐 |
≥98% |
23239-51-2 |
250mg,1g,5g |
β-2肾上腺素能受体 |
|
|
|
|
|
|
|
| D129813 |
Dexmedetomidine HCl |
≥98% |
145108-58-3 |
5mg,10mg,50mg,100mg |
α-2肾上腺素受体 |
|
|
|
|
|
|
|
| M129911 |
Medetomidine HCl |
≥99% |
86347-15-1 |
10mg,25mg,50mg,100mg |
α2-肾上腺素受体 |
|
1.08 nM |
|
|
|
|
|
| T101308 |
替扎尼定 |
98% |
64461-82-1 |
5g,25g |
α2-肾上腺素受体 |
|
|
|
|
|
|
|
| D129815 |
Detomidine HCl |
≥98% |
90038-01-0 |
50mg,250mg,1g |
|
|
|
|
|
|
|
|
| S129883 |
Scopine |
≥98% |
498-45-3 |
25mg,100mg,200mg,500mg |
α1-肾上腺素能受体 |
|
|
|
|
|
|
|
| N107258 |
重酒石酸去甲肾上腺素一水合物 |
≥98%（HPLC),USP |
108341-18-0 |
250mg,1g,5g,25g |
α-肾上腺素能受体 |
|
|
|
|
|
|
|
| X139232 |
赛拉嗪 |
≥98.0%(HPLC) |
7361-61-7 |
1g,5g,10g,25g |
α2-肾上腺素受体 |
|
|
|
|
|
|
|
| T128967 |
特布他林半硫酸盐 |
98% |
23031-32-5 |
1g,5g,25g |
β2-肾上腺素能受体 |
53 nM |
|
|
|
|
|
|
| T128967 |
特布他林半硫酸盐 |
分析标准品 |
23031-32-5 |
100mg |
β2-肾上腺素能受体 |
53 nM |
|
|
|
|
|
|
| I157589 |
异丙肾上腺素硫酸盐二水合物 |
>98.0%(HPLC)(N) |
299-95-6 |
1g,5g,25g |
β-肾上腺素能受体 |
|
|
|
|
|
|
|
| X129373 |
Xylometazoline HCl |
≥98.0%(HPLC) |
1218-35-5 |
1g,5g,25g,100g |
α2B肾上腺素受体 |
|
|
|
|
4 μM |
|
|
| A114817 |
双甲脒 |
分析标准品,99% |
33089-61-1 |
250mg |
α2肾上腺素受体 |
|
|
|
|
|
|
|
| A114818 |
双甲脒 |
97% |
33089-61-1 |
1g,5g |
α2肾上腺素受体 |
|
|
|
|
|
|
|
| G133358 |
Guanfacine hydrochloride |
≥98%(HPLC) |
29110-48-3 |
10mg,50mg,100mg,250mg |
α2A-肾上腺素受体 |
|
|
|
|
|
|
|
| I134069 |
异舒普林 盐酸盐 |
分析标准品 |
579-56-6 |
1g,5g |
β-肾上腺素能受体 |
|
|
|
|
|
|
|
| I125935 |
Indacaterol |
≥99% |
312753-06-3 |
50mg,250mg |
β1-肾上腺素能受体 |
|
|
7.36 |
|
|
|
|
| β2-肾上腺素能受体 |
|
|
5.48 |
|
|
|
|
| B134443 |
Bambuterol Hydrochloride |
≥98% (HPLC) |
81732-46-9 |
1g,5g |
β-肾上腺素能受体 |
|
|
|
|
|
|
|
| D134211 |
DL-去甲肾上腺素 盐酸盐 |
97% |
55-27-6 |
1g,5g,25g |
|
|
|
|
|
|
|
|
| S107339 |
辛弗林 |
分析标准品,≥98% |
94-07-5 |
20mg |
|
|
|
|
|
|
|
|
| S107340 |
辛弗林 |
98% |
94-07-5 |
5g,25g |
|
|
|
|
|
|
|
|
| N109573 |
L-去甲肾上腺素 |
98% |
51-41-2 |
250mg,1g |
α1肾上腺素受体 |
|
56 nM |
|
|
|
|
|
| α2A肾上腺素受体 |
|
330 nM |
|
|
|
|
|
| β1肾上腺素受体 |
|
740 nM |
|
|
|
|
|
| B136672 |
Brimonidine |
>98.0%(HPLC) |
59803-98-4 |
250mg,1g,5g |
|
|
|
|
|
|
|
|
| D137302 |
双氢麦角胺甲磺酸盐 |
>95.0%(HPLC) |
6190-39-2 |
100mg,250mg,1g |
|
|
|
|
|
|
|
|
| D135863 |
Dihydro Ergotamine Mesylate |
药典级 |
6190-39-2 |
250mg |
|
|
|
|
|
|
|
|
| A129906 |
Adrenalone HCl Hydrate |
≥98% |
62-13-5 |
1g,5g,25g,100g |
α-1肾上腺素受体 |
|
|
|
|
|
|
|
| D129628 |
醋酸去氧皮质酮 |
≥99% |
56-47-3 |
250mg,1g,5g |
|
|
|
|
|
|
|
|
*组胺受体
| 项目号 |
产品名称 |
规格 |
CAS |
包装 |
靶点 |
IC50 |
Ki |
| C115479 |
Cetirizine dihydrochloride |
98% |
83881-52-1 |
1g,5g,25g,100g |
组胺受体 |
|
|
| F129253 |
Fexofenadine HCl |
≥98% |
153439-40-8 |
10mg,50mg,1g,5g |
组胺H1受体 |
246 nM |
|
| E129640 |
Epinastine HCl |
≥99% |
108929-04-0 |
50mg,250mg,1g,5g,25g |
组胺受体 |
|
|
| O159894 |
Olopatadine Hydrochloride |
>98.0%(HPLC) |
140462-76-6 |
250mg,1g |
组胺受体 |
559 μM |
|
| A124055 |
安他唑啉 盐酸盐 |
98% |
2508-72-7 |
1g,5g,25g,100g |
组胺H1受体 |
|
|
| K124652 |
酮替芬延胡索酸 |
99% |
34580-14-8 |
100mg,250mg,1g,5g,25g |
组胺H1受体 |
|
|
| A129250 |
Azatadine dimaleate |
≥98% |
3978-86-7 |
10mg,50mg,250mg,1g |
组胺受体 |
6.5 nM |
|
| 胆碱能 |
10 nM |
|
| H107699 |
橙皮素 |
分析标准品,≥98% |
520-33-2 |
20mg |
组胺受体 |
|
|
| H107700 |
橙皮素 |
97% |
520-33-2 |
1g,5g,25g,100g |
组胺受体 |
|
|
| C136571 |
CarbinoxamineMaleateSalt |
- |
3505-38-2 |
5g,10g,25g |
组胺-H1受体 |
|
|
| D129627 |
Doxylamine Succinate |
≥99% |
562-10-7 |
1g,5g,10g,25g,50g |
组胺H1受体 |
|
|
| B102783 |
盐酸倍他司汀 |
99% |
5579-84-0 |
1g,5g,10g,25g,100g |
组胺H3受体 |
1.9 μM |
|
| C129211 |
Clemastine Fumarate |
≥98% (HPLC) |
14976-57-9 |
100mg,250mg,500mg,1g |
组胺H1受体 |
3 nM |
|
| L129669 |
Latrepirdine |
≥96% |
97657-92-6 |
5mg,10mg,50mg |
|
|
|
| L129223 |
Loratadine |
≥98% |
79794-75-5 |
100mg,1g,5g,25g |
B(0)AT2 |
4 μM |
|
| B129218 |
Bepotastine Besilate |
98% |
190786-44-8 |
10mg,50mg,100mg,250mg,1g |
|
|
|
| M129226 |
Mianserin HCl |
≥98% |
21535-47-7 |
50mg,250mg,1g,5g |
组胺受体 |
|
|
| M157977 |
美喹他嗪 |
>98.0%(GC) |
29216-28-2 |
100mg,250mg,1g |
组胺H1受体 |
|
|
| A129214 |
Azelastine HCl |
≥98%(HPLC) |
79307-93-0 |
100mg,250mg,1g,5g,25g |
组胺受体 |
|
|
| R129213 |
盐酸雷尼替丁 |
≥98%(HPLC) |
66357-59-3 |
1g,5g,25g |
组胺H2-受体 |
3.3±1.4 μM |
|
| D129201 |
Diphenhydramine Hydrochloride |
≥98% (HPLC) |
147-24-0 |
5g,25g,100g,500g |
组胺H1受体 |
|
|
| D155989 |
Desloratadine |
>98.0%(HPLC)(T) |
100643-71-8 |
100mg,250mg,1g,5g,25g |
组胺H1受体 |
51nM |
|
| C129233 |
马来酸氯苯那敏 |
≥99% |
113-92-8 |
5g,25g,100g,500g |
组胺H1受体 |
12nM |
|
| M129292 |
Meclizine 2HCl |
≥98% |
1104-22-9 |
250mg,1g,5g,25g |
组胺H1受体 |
|
|
| M129245 |
Mizolastine |
≥98% |
108612-45-9 |
1g,5g |
组胺H1受体 |
47 nM |
|
| C102301 |
Cimetidine |
99% |
51481-61-9 |
5g,25g,100g |
组胺H2受体 |
|
|
| L129237 |
Lafutidine |
≥99% |
118288-08-7 |
10mg,50mg,250mg |
组胺H2受体 |
|
|
| N129229 |
Nizatidine |
≥98% |
76963-41-2 |
5g,25g |
组胺H2受体 |
0.9 nM |
|
| AChE |
6.7 nM |
|
| H168667 |
羟嗪 二盐酸盐 |
98% |
2192-20-3 |
10mg,10g |
组胺H1受体 |
19 nM |
|
| B129275 |
Brompheniramine hydrogen maleate |
≥98% |
980-71-2 |
50mg,250mg,1g,5g,25g |
组胺H1受体 |
|
|
| J129258 |
JNJ-7777120 |
≥98% (HPLC) |
459168-41-3 |
10mg,50mg |
组胺H4受体 |
|
4.5 nM |
| P129261 |
Pemirolast potassium |
≥99% |
100299-08-9 |
10mg,50mg,250mg |
组胺H1受体 |
|
|
| L124802 |
盐酸左旋西替利嗪 |
≥98% (HPLC) |
130018-87-0 |
1g,5g |
组胺H1受体 |
|
|
| P129451 |
Pheniramine Maleate |
≥99% |
132-20-7 |
1g,5g |
|
|
|
| C119225 |
咳平盐酸盐 |
分析标准品 |
14984-68-0 |
5g,10g,25g |
|
|
|
| R129246 |
盐酸罗沙替丁醋酸酯 |
≥99% |
93793-83-0 |
200mg,1g,5g,25g |
组胺H2受体 |
3.2 μM |
|
| A151022 |
阿伐斯汀 |
>98.0%(HPLC) |
87848-99-5 |
20mg,100mg |
|
|
|
| E134559 |
富马酸依美斯汀 |
≥98.0%(HPLC) |
87233-62-3 |
50mg,250mg,1g,5g |
组胺H1受体 |
|
|
| M118323 |
美海屈林萘二磺酸盐 |
98% |
6153-33-9 |
1g,5g,25g |
|
|
|
| F129242 |
Famotidine |
≥99% |
76824-35-6 |
5g,25g |
组胺H2受体 |
0.6 mM |
|
| P133927 |
盐酸异丙嗪 |
>98.0%(HPLC) |
58-33-3 |
25g,100g |
组胺H1受体 |
|
|
| L129221 |
Lidocaine |
≥99% |
137-58-6 |
5g,25g,100g |
组胺H1受体 |
>32 μM |
|
| H111796 |
组胺 |
96% |
51-45-6 |
1g,5g |
|
|
|
| H110868 |
组胺二盐酸盐 |
98% |
56-92-8 |
5g,25g,100g |
组胺H1受体 |
|
|
| 组胺H2受体 |
|
|
| B152161 |
甲磺酸倍他司汀 |
>99.0%(HPLC) |
54856-23-4 |
25g,100g,500g |
|
|
|
|
|